ConCallIQ
Go Pro
Home › Emcure Pharmaceuticals › Revenue History

Emcure Pharmaceuticals Revenue History — Quarter by Quarter

Emcure Pharmaceuticals's revenue moved from ₹2,100 Cr in Q1 FY26 to ₹2,470 Cr in Q4 FY26, a 17.6% change over 3 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

QuarterRevenue (₹ Cr)YoY Change
Q4 FY26₹2,470 Cr+16.7%
Q3 FY26₹2,363 Cr+20.4%
Q1 FY26₹2,100 Cr+15.7%

What management said about revenue

G

Q4 FY26 · FY27 revenue growth: low-to-mid teens

Management expects revenue growth in the low-to-mid teen percentage range for FY27, assuming stable macro conditions.

G

Q4 FY26 · Semaglutide (Pista) steady growth in FY27

Aim for steady growth of the semaglutide brand Pista in FY27, leveraging competitive pricing and clinical differentiation.

G

Q3 FY26 · Revenue growth of low-to-mid teens CAGR over 3-5 years

Management aspires for a low-to-mid teens compounded revenue growth rate, driven by domestic outperformance and international expansion.

G

Q1 FY26 · Sanofi diabetes portfolio to add ~₹200 crore annualized revenue

The acquired oral diabetes portfolio from Sanofi (brands Emeril and Pain) is expected to contribute ~₹200 crore on an annualized basis, with ~8 months of revenue in FY26.